📊 LFCR Key Takeaways
Is Lifecore Biomedical, Inc.. de (LFCR) a Good Investment?
LifeCore Biomedical is in severe financial distress with negative shareholders' equity (-$28.4M) and inability to cover interest expenses from operations (coverage ratio: -0.6x). The company's massive debt burden ($148.7M) relative to revenue ($23.2M) creates existential solvency risk, though positive free cash flow ($3.6M) provides temporary relief.
Fundamentals are weak: the company is loss-making with a -32% net margin and negative ROA, while operating income does not cover interest expense. The balance sheet carries heavy leverage and negative equity, elevating refinancing and solvency risk despite decent liquidity. Breakeven free cash flow and a 25% gross margin offer some cushion, but sustained margin expansion and deleveraging are needed before the risk profile improves.
Lifecore Biomedical, Inc.. de Key Strengths (LFCR)
- Positive operating cash flow of $4.7M despite significant net losses, suggesting non-cash charges (depreciation/R&D) are major factors
- Free cash flow generation of $3.6M with 15.4% FCF margin demonstrates some operational cash generation
- Adequate short-term liquidity with current ratio of 3.79x and cash position of $20.8M
- Solid liquidity (current and quick ratios) provides near-term cushion
- Positive operating cash flow and roughly breakeven FCF
- Moderate gross margin (25%) indicates some pricing power/cost discipline
LFCR Stock Risks: Lifecore Biomedical, Inc.. de Investment Risks
- Negative shareholders' equity of -$28.4M indicates technical insolvency and liabilities exceeding asset values
- Interest coverage ratio of -0.6x with negative operating income ($4.7M loss) - cannot service debt from operations
- Extreme leverage with debt-to-revenue ratio of 6.4x ($148.7M debt / $23.2M revenue); minimal cash runway
- Deeply unprofitable with net margin of -64.6% and negative operating margin of -20.1%
- Pharmaceutical sector execution risk with high R&D spending and long product development cycles
- Negative equity and high long-term debt increase financial risk
- Operating losses with negative interest coverage threaten debt service
- Thin free cash flow limits reinvestment and deleveraging capacity
Key Metrics to Watch
- Quarterly revenue trends and pipeline progress milestones
- Operating cash flow sustainability and cash burn rate
- Debt refinancing events and covenant compliance status
- Gross margin expansion trajectory
- Operating income path to positive territory
- Interest coverage
- Free cash flow margin
Lifecore Biomedical, Inc.. de (LFCR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.79x current ratio provides a solid financial cushion.
LFCR Profit Margin, ROE & Profitability Analysis
LFCR vs Healthcare Sector: How Lifecore Biomedical, Inc.. de Compares
How Lifecore Biomedical, Inc.. de compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lifecore Biomedical, Inc.. de Stock Overvalued? LFCR Valuation Analysis 2026
Based on fundamental analysis, Lifecore Biomedical, Inc.. de has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lifecore Biomedical, Inc.. de Balance Sheet: LFCR Debt, Cash & Liquidity
LFCR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lifecore Biomedical, Inc.. de's revenue has declined by 78% over the 5-year period, indicating business contraction. The most recent EPS of $0.33 reflects profitable operations.
LFCR Revenue Growth, EPS Growth & YoY Performance
LFCR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $23.2M | -$10.0M | $-0.29 |
| Q3 2025 | $35.2M | -$14.8M | $0.42 |
| Q2 2025 | $30.2M | $3.5M | $0.10 |
| Q1 2025 | $24.5M | -$10.8M | $-0.35 |
| Q3 2024 | $26.5M | -$10.8M | $0.42 |
| Q2 2024 | $21.9M | $3.5M | $0.10 |
| Q1 2024 | $23.7M | -$10.8M | $-0.35 |
| Q3 2023 | $27.6M | -$9.5M | $-0.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lifecore Biomedical, Inc.. de Dividends, Buybacks & Capital Allocation
LFCR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lifecore Biomedical, Inc.. de (CIK: 0001005286)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LFCR
What is the AI rating for LFCR?
Lifecore Biomedical, Inc.. de (LFCR) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LFCR's key strengths?
Claude: Positive operating cash flow of $4.7M despite significant net losses, suggesting non-cash charges (depreciation/R&D) are major factors. Free cash flow generation of $3.6M with 15.4% FCF margin demonstrates some operational cash generation. ChatGPT: Solid liquidity (current and quick ratios) provides near-term cushion. Positive operating cash flow and roughly breakeven FCF.
What are the risks of investing in LFCR?
Claude: Negative shareholders' equity of -$28.4M indicates technical insolvency and liabilities exceeding asset values. Interest coverage ratio of -0.6x with negative operating income ($4.7M loss) - cannot service debt from operations. ChatGPT: Negative equity and high long-term debt increase financial risk. Operating losses with negative interest coverage threaten debt service.
What is LFCR's revenue and growth?
Lifecore Biomedical, Inc.. de reported revenue of $23.2M.
Does LFCR pay dividends?
Lifecore Biomedical, Inc.. de does not currently pay dividends.
Where can I find LFCR SEC filings?
Official SEC filings for Lifecore Biomedical, Inc.. de (CIK: 0001005286) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LFCR's EPS?
Lifecore Biomedical, Inc.. de has a diluted EPS of $-0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LFCR's fundamental grade?
Based on our AI fundamental analysis in May 2026, Lifecore Biomedical, Inc.. de has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LFCR stock overvalued or undervalued?
Valuation metrics for LFCR: ROE of N/A (sector avg: 15%), net margin of -64.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LFCR's AI grade for 2026?
Our dual AI analysis gives Lifecore Biomedical, Inc.. de a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LFCR's free cash flow?
Lifecore Biomedical, Inc.. de's operating cash flow is $4.7M, with capital expenditures of $1.1M. FCF margin is 15.4%.
How does LFCR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -64.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 3.79 (avg: 2).